基于真实世界喜炎平注射液治疗肺部感染的联合用药关联分析

运用关联规则方法分析真实世界中使用喜炎平注射液(简称喜炎平)患者的联合用药规律.通过选取全国18家三级甲等医院中使用喜炎平的5 822例患者,研究其患有肺部感染患者的联合用药信息,运用Apriori算法及关联规则方法分析.结果显示喜炎平治疗肺部感染时主要联合用药有复方氨基酸、肌苷、辅酶A、三磷酸胞苷、维生素C等.喜炎平常用合并用药可分为5类:营养支持疗法(主要为维生素C、复方氨基酸)、辅酶类(辅酶A、三磷酸腺苷、肌苷)、化痰平喘类(氨溴索、多索茶碱、沙丁胺醇)、激素类(地塞米松、布地奈德)、抗生素(主要为头孢米诺).主要合并药物基本符合肺部感染用药规律.另外,喜炎平最常合并用药模式:1种联合用药时为喜炎平+营养支持疗法,2种或2种以上联合用药时为喜炎平+营养支持疗法+辅酶类药;从药理作用看,喜炎平多与药理作用相似的西药联合应用,在治疗肺部感染时起到替代或补充抗生素作用,但其联合用药的安全性、合理性还需要结合临床实际进一步探讨,以期为临床用药提供参考.

Correlation analysis on combined medication with of Xiyanping injection in treatment of lung infection in real world

To analyze the regularity in combined medication with Xiyanping injection (Xiyanping for short) in the real world by association rules. Totally 5 822 patients using Xiyanping injection was collected from the 18 Class III Grade I hospitals nationwide to study the combined medication information of the patient with lung infection and make the analysis by using association rules and Apriori. According to the results, major drugs combined with Xiyanping in treatment of lung infection included compound amino acid, inosine, coenzyme A, cytidine triphosphate, vitamin C. Common drugs combined with Xiyanping can be divided into 5 categories: nutrition support therapy (vitamin C, compound amino acid), coenzymes (coenzyme A, cytidine triphosphate, inosine), expectorants and antiasthmatics (ambroxol, salbutamol, doxofylline), hormones (dexamethasone, budesonide), antibiotics (mainly cefminox). The main combined medicines mostly conformed to the regularity for drugs treating lung infection. In addition, there were two most common medical combination models: the model for Xiyanping combined a single medicine is Xiyanping+nutrition support therapy, while the model for Xiyanping combined two or more than two medicines is Xiyanping+nutrition support therapy + coenzyme. Pharmacologically, Xiyanping is mostly combined with western medicines with similar pharmacological effects to substitute or supplement the antibiotic effect in treating lung infection. However, further studies shall be conducted for the safety and rationality of the combined medication based on clinical practices, in order to provide reference for clinical medication.